Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Diagnostic
- Drugs
- Assay
- Disease
- Biotechnology
- Diagnostic Substances
- Medical
- Test/Monitoring
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 329699
Licensor agrees to grant the following options to the following third parties
(a) For a period of six (6) months following June 22, 1999, Licensor will grant an option for a license under the Collins Patents. The terms of the license will be the same, except that such terms shall not include a license issue fee as provided herein and the license will be granted solely for purposes of the blood screening aspects.
(b) For a period of six (6) months following June 22, 1999, Licensor will grant an option for a license under the Collins Patents. The terms of the license will be the same, except that such terms shall not include a license issue fee as provided herein and the license will be granted solely for purposes of infectious diseases aspects, with the exception of blood screening.
(c) For a period of twelve (12) months following June 22, 1999, Licensor will grant an option for a license under the Collins Patents at terms similar to the terms granted.
(d) For a period of six (6) months following the grant by Licensee of a Licensee Core Technology License in a field of infectious disease nucleic acid testing to a Licensee Core Licensee, Licensor will grant to the Licensee Core Licensee an option to a license under the Collins Patents in the same field of infectious disease nucleic acid testing. The license under the Collins Patents shall be at reasonable commercial terms which are no greater than those terms granted by Licensor to other comparable Collins Licensees and include a most favored licensee provision relative to such other comparable Collins Licensees.
Target And Background Capture Methods And Apparatus For Affinity Assays by Collins,
Target And Background Capture Methods With Amplification For Affinity Assays by Collins, et al,
Closed Vessel For Isolating Target Molecules And For Performing Amplification by Neri, et al., and,
Methods And Composition For Preventing Interference With Affinity Capture Schemes by Collins, et al.
IPSCIO Record ID: 108
IPSCIO Record ID: 329692
By this agreement, the Parties shall cooperate in the Development Transition and in the transfer of any information and Know-How necessary for Licensee to assume the development of the ANAIS Products.
Licensor grants a non-exclusive, non-transferable, worldwide license in the ANAIS Field to use the Licensor Technology to develop, make and have made, use, sell, offer for sale, have sold, and import the ANAIS Products, solely and exclusively for use on the ANAIS Instrumentation.
Key BioChemistry Components include
– All enzymes used in transcription-based amplification for use in ANAIS Assays.
– All biochemical components used for amplification of amplicon of target with TMA, which is Licensors patents and technology relating to Nucleic Acid Sequence Amplification Methods.
– All probes, primers, and oligonucleotides used in ANAIS Assays.
– Nucleic acids used for ,positive and negative controls, standards, calibrators, and for quality control of ANAIS Assay components.
ANAIS products shall mean the following Probe Assays, in each case made, used, or sold under the license granted by Licensor and solely and exclusively for use on ANAIS Instrumentation
– Probe Assays for the detection, identification, quantification, and/or susceptibility testing for panels of microorganisms or agents (but specifically excluding single organisms) in specimens taken from humans, solely for the purpose of diagnosis and medical care of the persons from whom the tested samples were taken. A panel shall test for 10 or more distinct species of organisms or agents in the following groups of microorganisms
or agents Bacteria; Viruses; Yeast/Fungi; or, Parasites.The panels shall be medically relevant.
– Probe Assays for the detection, identification, quantification, and/or susceptibility testing for an individual organism, drawn only from the groups or families listed below, in specimens taken from humans, solely for the purpose of diagnosis and medical care of the persons from whom the tested samples were taken Hepatitis virus; HIV virus; Herpes virus; Human papilloma virus; HTLV Virus; Yeast; Fungus; Parasite; and, Bacterium other than Neisseria gonorrhoeae or Chlamydia trachomatis.
– Probe Assays for testing of sequences encoding human leukocyte antigens in specimens taken from humans and/or
– Probe Assays to detect and /or precisely identify microorganisms or agents including bacteria, yeast, viruses and parasites for use in quality control processes of water, food products, and/or previously developed pharmaceutical or cosmetic products, and/or identify foods coming or derived from plants and/or/ animals for the purpose of confirming anticipated source(s) of the food.
Assay shall mean a diagnostic process or procedure applied to a sample, or a portion of a sample, whereby a particular chemical compound, or a collection of compounds, or a portion of a chemical compound, is detected and optionally quantified.
– the detection, identification, quantification, and/or susceptibility testing of organisms or agents causing human clinical infectious diseases, as present in the human body, solely for the purpose of diagnosis and medical care of the persons from whom the tested samples were taken;
– testing for sequences encoding human leukocyte antigens;
– testing for microorganisms or agents, including bacteria, yeast, viruses and parasites in quality control processes of water, food products, and/or previously developed pharmaceutical or cosmetic products; and/or
– testing for the purposes of identifying genetically-modified foodstuffs or identifying animal species in foodstuffs.
The ANAIS Field specifically does not include testing for infectious agents in blood and blood products intended for transfusion, or the testing for infectious agents in blood in connection with organ transplants, or the testing of specimens from non-human animals or environmental sources except as specifically provided above, even if such testing is for the purpose of detecting or identifying organisms which are associated with infectious diseases in man.
IPSCIO Record ID: 237263
Licensor grants a world-wide, non-exclusive, nontransferable license, without the right to sublicense, to make, use, sell, off er for sale and import Licensed Products for genotyping HAPâ„¢ Markers in all fields other than human and animal infectious diseases. Excluded from this grant is the right to make, sell, offer for sale or import the Licensors ProbeTecâ„¢ ET.
The patents include, but are not limited to, Nucleic Acid Target Generation, Oligonucleotides for amplification and detection of hemochromatosis, and, Methods for detecting nucleic acid sequence variations.
Licensed Products shall mean any device, instrument, service, kit, composition of matter, material, product or component thereof that utilizes Licensed Know-How.
Instrument shall mean the Licensors ProbeTecâ„¢ ET installed in Licensees HAPâ„¢ Typing facility in New Haven, CT.
HAPâ„¢ Marker shall mean a polymorphism or any ordered combination of two or more polymorphisms present at a locus on a single chromosome that is contained in the Licensee HAPâ„¢ Database during the term of this Agreement or that is discovered from any gene where such discovery was made solely by employees of Licensee or others acting on behalf of Licensee, or, jointly by employees of Licensees or others acting on its behalf and employees of a HAPâ„¢ Partner or others acting on its behalf or for which a HAPâ„¢ Partner requests Licensee to develop genotyping assays or provide genotype data.
Licensor ProbeTecâ„¢ ET shall mean the clinical platform for infectious disease testing owned by Licensor using Strand Displacement Amplification Technology or SDA Technology and real time detection means.
LICENSED PATENTS
1. US Patent No. 5,270,184, entitled 'Nucleic Acid Target Generation'
2. US Patent No. 5,422,252, entitled 'Simultaneous Amplification of Multiple Targets'
3. US Patent No. 5,455,166, entitled 'Strand Displacement Amplification'
4. US Patent No. 5,536,649, entitled 'Decontamination of Nucleic Acid Amplification Reactions'
5. US Patent No. 5,547,861, entitled 'Detection of nucleic acid amplification'
6. US Patent No. 5,648,211, entitled 'Strand Displacement Amplifcation Using Thermophilic Enzymes'
7. US Patent No. 5,624,825, entitled 'Simultaneous Amplification of Multiple Targets'
8. US Patent No. 5,691,145, entitled 'Detection of nucleic acids using G-quartets'
9. US Patent No. 5,712,124, entitled 'Strand Displacement Amplification'
10. US Patent No. 5,736,365 entitled 'Multiplex nucleic acid amplification'
11. US Patent No. 5,744,311 entitled 'Strand displacement amplification using thermophilic enzymes'
12. US Patent No. 5,840,487, entitled 'Internal controls for isothermal nucleic acid amplification reactions'
13. US Patent No. 5,863,736, entitled 'Method, apparatus and computer program products for determining quantities of nucleic acid sequences in samples'
14. US Patent No. 5,888,739, entitled 'Detection of nucleic acids using G-quartets and Itetraplexes'
15. US Patent No. 5,916,779, entitled 'Strand displacement amplification of RNA
targets'
16. US Patent No. 5,919,630, entitled 'Detection of nucleic acids by fluorescence quenching'
17. US Patent No. 5,928,869, entitled 'Detection of nucleic acids by fluorescence quenching'
18. US Patent No. 5,935,791, entitled 'Detection of nucleic acids by fluorescence quenching'
